TSIEX03:	Study Treatment Administration; Safety Analysis Set (Study jjcs - core)					
 	Active Study Agent 	Active Study Agent 	Active Study Agent 	 	
 	Xanomeline High Dose 	Xanomeline Low Dose 	Combined 	Placebo 	
Parameter 	N=53 	N=73 	N=126 	N=59 	
Total number of administrations 	 	 	 	 	
N 	53 	73 	126 	59 	
Mean (SD) 	12.6 (9.24) 	15.0 (8.78) 	14.0 (9.02) 	16.1 (9.01) 	
Median 	11.0 	16.0 	15.0 	17.0 	
Min, max 	0, 29 	0, 29 	0, 29 	0, 30 	
Interquartile range 	4.0, 21.0 	7.0, 23.0 	5.0, 22.0 	8.0, 24.0 	
 	 	 	 	 	
Total number of administrations, n (%) 	 	 	 	 	
1 to <10 	19 (38.0%) 	21 (29.6%) 	40 (33.1%) 	15 (26.3%) 	
10 to <20 	13 (26.0%) 	22 (31.0%) 	35 (28.9%) 	15 (26.3%) 	
≥20 	18 (36.0%) 	28 (39.4%) 	46 (38.0%) 	27 (47.4%) 	
 	 	 	 	 	
Total number of administrationsa, n (%) 	 	 	 	 	
≥1 	53 (100.0%) 	73 (100.0%) 	126 (100.0%) 	59 (100.0%) 	
≥2 	47 (88.7%) 	68 (93.2%) 	115 (91.3%) 	56 (94.9%) 	
≥3 	45 (84.9%) 	66 (90.4%) 	111 (88.1%) 	54 (91.5%) 	
≥5 	36 (67.9%) 	61 (83.6%) 	97 (77.0%) 	50 (84.7%) 	
≥10 	31 (58.5%) 	50 (68.5%) 	81 (64.3%) 	42 (71.2%) 	
 	 	 	 	 	
Cumulative dose ([units]) 	 	 	 	 	
N 	53 	73 	126 	59 	
Mean (SD) 	2799.3 (1430.11) 	2558.4 (1472.53) 	2659.7 (1453.97) 	2520.5 (1474.47) 	
Median 	3301.0 	2465.0 	2884.5 	2660.0 	
Min, max 	298, 4927 	102, 4978 	102, 4978 	187, 4963 	
Interquartile range 	1561.0, 3984.0 	1177.0, 3859.0 	1326.0, 3914.0 	1118.0, 4098.0 	

a Subjects are summarized in all applicable duration categories. 	
a Subjects are summarized in all applicable duration categories.	
a Subjects are summarized in all applicable duration categories.	
a Subjects are summarized in all applicable duration categories.	
a Subjects are summarized in all applicable duration categories.